Effectiveness of XBB.1.5 Vaccines Against Symptomatic SARS‐CoV‐2 Infection in Older Adults During the JN.1 Lineage‐Predominant Period, European VEBIS Primary Care Multicentre Study, 20 November 2023–1 March 2024
Lore Merdrignac, Charlotte Lanièce Delaunay, Nuno Verdasca, Lorena Vega‐Piris, Joan O’Donnell, Noémie Sève, Camino Trobajo‐Sanmartín, Silke Buda, Mariëtte Hooiveld, Ana Paula Rodrigues, Gergő Túri, Neus Latorre‐Margalef, Ivan Mlinarić, Mihaela Lazăr, Marine Maurel, Daniel Castrillejo, Charlene Bennett, Marie‐Anne Rameix‐Welti, Iván Martínez‐Baz, Ralf Dürrwald, Adam Meijer, Aryse Melo, Beatrix Oroszi, Tove Samuelsson Hagey, Sanja Filipović, Frederika Dijkstra, Verónica Gomez, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling, the VEBIS Primary Care Vaccine Effectiveness Group
Abstract
We estimated XBB.1.5 vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infection among adults aged ≥ 65 years during the 2023/2024 JN.1 lineage-predominant period in a European multi-country test-negative case-control study at primary care level. We estimated VE adjusted by study site, age, sex, chronic conditions and onset date. We included 220 cases and 1733 controls. The VE was 48% (95% CI: 12-71), 23% (95% CI: -11-48) and 5% (95% CI: -92-56) among those with symptom onset 1-5, 6-11, and ≥ 12 weeks after vaccination, respectively. XBB.1.5 vaccine provided short and moderate protection against JN.1 symptomatic infection.